2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
685
Carcinoma, Non-Small-Cell Lung
328
Neoplasms
170
Breast Neoplasms
166
Lung Neoplasms
158
Urinary Bladder Neoplasms
157
Neoplasm Metastasis
140
Cholangiocarcinoma
114
Ovarian Neoplasms
106
Biliary Tract Neoplasms
95
Lymphoma, Large B-Cell, Diffuse
73
Nasopharyngeal Carcinoma
71
Lymphoma
66
Sarcoma
63
Recurrence
62
Gallbladder Neoplasms
61
Carcinoma, Transitional Cell
56
Triple Negative Breast Neoplasms
54
Hodgkin Disease
52
Colorectal Neoplasms
49
Lymphoma, Non-Hodgkin
48
Fallopian Tube Neoplasms
48
Adenocarcinoma
45
Bile Duct Neoplasms
40
Carcinoma, Ovarian Epithelial
31
Non-Muscle Invasive Bladder Neoplasms
30
Uterine Cervical Neoplasms
28
Carcinoma
28
Unspecified Adult Solid Tumor, Protocol Specific
27
Adenocarcinoma of Lung
27
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
Gemcitabine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled